세계의 포유류 폴리클로널 IgG 항체 시장 보고서 : 유형, 제품, 용도, 최종 용도, 지역별(2024-2032년)

The global mammalian polyclonal IgG antibody market size reached US$ 1,092.2 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,648.4 Million by 2032, exhibiting a growth rate (CAGR) of 4.54% during 2024-2032.

Mammalian polyclonal immunoglobulins (IgG) antibody refers to antigens or vaccinations that are manufactured through inoculation of various mammals, including mice, rabbits, and goats. During this procedure, an antigen is administered via injectable into the mammal body to activate the B-lymphocytes that supply IgG. These antibodies are used in labeling reagents in multiple immunoassay tests, including enzyme-linked immunosorbent assay (ELISA), western blot tests, immunoradiometric assay (IRMA), and radioimmunoassay (RIA). Apart from this, the process does not require skilled professionals to produce large batches of vaccinations. Mammalian polyclonal IgG antibody helps create multiple therapeutics, diagnose various ailments, and perform antibody identification and flow cytometry. As a result, they find extensive applications in biochemical research to detect denatured proteins and examine diseases and their treatments. At present, they are commercially available in cardiac, metabolic, and renal marker product variants.

Mammalian Polyclonal IgG Antibody Market Trends:

The increasing prevalence of various chronic disorders, including cancer and autoimmune ailments, and the rising need for antibodies for multiple immunoassay tests and therapeutic and analytical applications in research settings are primarily driving the market growth. In line with this, significant investments in biotechnology and pharmaceutical companies by governments to formulate effective novel vaccinations and injectables through advanced technologies are acting as another growth-inducing factor. Additionally, the ongoing innovation of creative mammalian antibodies by biopharma organizations for quality control (QC) is contributing to the market growth. Moreover, the escalating biomarkers approval and their extensive usage by clinicians for accurate and rapid diagnosis of B-cell lymphoma and leukemia are supporting the market growth. Apart from this, significant enhancements in the healthcare infrastructure and research and development (R&D) activities to enhance antibody efficacy are creating a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global mammalian polyclonal IgG antibody market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, product, application, and end use.

Breakup by Type:

Goat

Rabbit

Horse

Mouse

Others

Breakup by Product:

Cardiac Markers

Metabolic Markers

Renal Markers

Others

Breakup by Application:

ELISA

Immunoturbidimetry

Immunoelectrophoresis

Antibody Identification

Immunohistochemistry

Immunocytochemistry

Western Blotting

Breakup by End Use:

Hospitals

Diagnostic Centers

Academic and Research Institutes

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbiotec Inc., Abcam plc, Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., Creative Diagnostics, Elabscience Biotechnology Inc., Geno Technology Inc., Merck KGaA, Proteintech Group Inc., STEMCELL Technologies Inc. and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

• 1. How big is the global mammalian polyclonal IgG antibody market?
• 2. What is the expected growth rate of the global mammalian polyclonal IgG antibody market during 2024-2032?
• 3. What are the key factors driving the global mammalian polyclonal IgG antibody market?
• 4. What has been the impact of COVID-19 on the global mammalian polyclonal IgG antibody market?
• 5. What is the breakup of the global mammalian polyclonal IgG antibody market based on the type?
• 6. What is the breakup of the global mammalian polyclonal IgG antibody market based on the product?
• 7. What is the breakup of the global mammalian polyclonal IgG antibody market based on the application?
• 8. What is the breakup of the global mammalian polyclonal IgG antibody market based on the end use?
• 9. What are the key regions in the global mammalian polyclonal IgG antibody market?
• 10. Who are the key players/companies in the global mammalian polyclonal IgG antibody market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Mammalian Polyclonal IgG Antibody Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Goat
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Rabbit
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Horse
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Mouse
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Others
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Product

• 7.1 Cardiac Markers
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Metabolic Markers
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Renal Markers
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Application

• 8.1 ELISA
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Immunoturbidimetry
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Immunoelectrophoresis
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Antibody Identification
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Immunohistochemistry
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast
• 8.6 Immunocytochemistry
  • 8.6.1 Market Trends
  • 8.6.2 Market Forecast
• 8.7 Western Blotting
  • 8.7.1 Market Trends
  • 8.7.2 Market Forecast

9 Market Breakup by End Use

• 9.1 Hospitals
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Diagnostic Centers
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Academic and Research Institutes
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Abbiotec Inc.
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
  • 15.3.2 Abcam plc
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 Bio-Rad Laboratories Inc.
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 Cell Signaling Technology Inc.
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
  • 15.3.5 Creative Diagnostics
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 Elabscience Biotechnology Inc.
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
  • 15.3.7 Geno Technology Inc.
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
  • 15.3.8 Merck KGaA
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Proteintech Group Inc.
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
  • 15.3.10 STEMCELL Technologies Inc.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
  • 15.3.11 Thermo Fisher Scientific Inc.
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
    • 15.3.11.4 SWOT Analysis